Search Results - Yuko Oya

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

    The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib? by Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi

    Published 2024
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

    Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer by Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Masashi Mikubo, Chiaki Kondo, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma

    Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma by Kosuke Tanaka, Toyoaki Hida, Yuko Oya, Tatsuya Yoshida, Junichi Shimizu, Tetsuya Mizuno, Hiroaki Kuroda, Noriaki Sakakura, Kenichi Yoshimura, Yoshitsugu Horio, Yukinori Sakao, Yasushi Yatabe

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma

    EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma by Kosuke Tanaka, Toyoaki Hida, Yuko Oya, Tomoyo Oguri, Tatsuya Yoshida, Junichi Shimizu, Yoshitsugu Horio, Akito Hata, Reiko Kaji, Shiro Fujita, Yoshitaka Sekido, Takeshi Kodaira, Masaki Kokubo, Nobuyuki Katakami, Yasushi Yatabe

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

    A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC by Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Koji Haratani, Shoichi Itoh, Takehiro Uemura, Ryotaro Morinaga, Takayuki Takahama, Kazuhisa Nakashima, Motoko Tachihara, Go Saito, Junko Tanizaki, Kohei Otsubo, Satoshi Ikeda, Hirotaka Matsumoto, Satoshi Hara, Akito Hata, Takeshi Masuda, Nobuyuki Yamamoto

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

    Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target by Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L. Lochmann, Yoshiko Murakami, Neha U. Patel, Jungoh Ham, Bin Hu, Krista M. Powell, Colin M. Coon, Brad E. Windle, Yuko Oya, Jennifer E. Koblinski, Hisashi Harada, Joel D. Leverson, Andrew J. Souers, Aaron N. Hata, Sosipatros A. Boikos, Yasushi Yatabe, Hiromichi Ebi, Anthony C. Faber

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: